Citadel Advisors
PHAT icon

Citadel Advisors’s Phathom Pharmaceuticals PHAT Stock Holding History

Citadel Advisors’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.01M Sell
184,901
-198,157
-52% -$2.26M ﹤0.01% 6552
2026
Q1 		$4.26M Buy
383,058
+71,743
+23% +$906K ﹤0.01% 4606
2025
Q4 		$5.16M Sell
311,315
-197,405
-39% -$2.82M ﹤0.01% 4241
2025
Q3 		$5.99M Buy
+508,720
New +$5.25M ﹤0.01% 4031
2025
Q2 		– Sell
-179,721
Closed -$994K – 14460
2025
Q1 		$1.13M Buy
179,721
+107,714
+150% +$654K ﹤0.01% 6702
2024
Q4 		$585K Sell
72,007
-148,396
-67% -$1.84M ﹤0.01% 8215
2024
Q3 		$3.98M Buy
220,403
+141,587
+180% +$1.98M ﹤0.01% 4317
2024
Q2 		$812K Sell
78,816
-46,829
-37% -$482K ﹤0.01% 7013
2024
Q1 		$1.33M Buy
125,645
+114,112
+989% +$969K ﹤0.01% 6336
2023
Q4 		$105K Sell
11,533
-264,194
-96% -$2.28M ﹤0.01% 10868
2023
Q3 		$2.86M Buy
275,727
+258,812
+1,530% +$3.55M ﹤0.01% 4562
2023
Q2 		$242K Sell
16,915
-171,569
-91% -$1.98M ﹤0.01% 9476
2023
Q1 		$1.35M Buy
188,484
+186,731
+10,652% +$1.64M ﹤0.01% 6144
2022
Q4 		$19.7K Buy
+1,753
New +$18.1K ﹤0.01% 13156
2022
Q3 		– Sell
-25,012
Closed -$238K – 13349
2022
Q2 		$212K Buy
+25,012
New +$257K ﹤0.01% 10583
2022
Q1 		– Sell
-11,466
Closed -$185K – 14337
2021
Q4 		$226K Sell
11,466
-7,944
-41% -$187K ﹤0.01% 11599
2021
Q3 		$623K Sell
19,410
-60,964
-76% -$2.03M ﹤0.01% 9337
2021
Q2 		$2.72M Buy
80,374
+71,833
+841% +$2.57M ﹤0.01% 5845
2021
Q1 		$321K Sell
8,541
-3,535
-29% -$148K ﹤0.01% 10698
2020
Q4 		$401K Buy
12,076
+5,360
+80% +$217K ﹤0.01% 8565
2020
Q3 		$246K Buy
+6,716
New +$233K ﹤0.01% 8467
2020
Q2 		– Sell
-11,948
Closed -$308K – 10326
2020
Q1 		$308K Buy
+11,948
New +$399K ﹤0.01% 7296

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Citadel Advisors's PHAT Position: Q2 2026 in Review

Citadel Advisors reduced its Phathom Pharmaceuticals (PHAT) stake by 52% in Q2 2026, selling an estimated $2.26M and leaving 184,901 shares worth $2.01M. The position accounts for ﹤0.01% of the portfolio, ranked #6552.

Citadel Advisors first reported a position in PHAT in Q1 2020 and has held it in 22 quarters since. The position peaked at $5.99M in Q3 2025. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Citadel Advisors held 184,901 shares of Phathom Pharmaceuticals worth $2.01M as of Q2 2026.
  • Citadel Advisors sold 198,157 Phathom Pharmaceuticals shares in Q2 2026, an estimated $2.26M.
  • Phathom Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #6552 holding.
  • Citadel Advisors first reported a position in Phathom Pharmaceuticals in Q1 2020 and has held it in 22 quarters since.
  • Citadel Advisors's Phathom Pharmaceuticals position peaked at $5.99M in Q3 2025.
  • 162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.